SPIRIT IV: Everolimus-Eluting Stent Sustains Advantage over Paclitaxel-Eluting Stent at 2 Years

Print  |  
Monday, August 20, 2007
By TCT Daily Staff
Thursday, September 23, 2010

WASHINGTON, DC—Two late-breaking clinical trials at TCT 2010 have demonstrated that Xience V, a second-generation DES, produces superior and sustained benefits over the standard Taxus stent.


For SPIRIT IV, researchers randomized 3,687 patients in a 2:1 ratio to treatment with the everolimus-eluting Xience V stent (Abbott Vascular) or the paclitaxel-eluting Taxus Express stent (Boston Scientific).

Gregg W. Stone, MD, of Columbia University Medical Center, New York, N.Y., presented data showing that, compared with the paclitaxel-eluting stent, the everolimus-eluting stent continued to reduce the primary composite endpoint of target lesion failure (a composite of cardiac death, target-vessel MI or ischemia-driven target lesion ....

You must be logged in to access this content.

To continue, please enter your username and password above.

If you do not yet have a free TCTMD account, please:

Register Now

For questions regarding the registration process, please refer to our FAQ documentation or contact customer service.